BioCryst Pharmaceuticals
BCRX
154 hedge funds and large institutions have $427M invested in BioCryst Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 43 reducing their positions, and 35 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 43
5% less call options, than puts
Call options by funds: $4.4M | Put options by funds: $4.64M
3.24% less ownership
Funds ownership: 75.5% → 72.26% (-3.2%)
7% less funds holding
Funds holding: 165 → 154 (-11)
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
33% less capital invested
Capital invested by funds: $635M → $427M (-$208M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$16.2M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.48M |
| 3 |
BlackRock
New York
|
+$5.47M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$3.89M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$15.9M |
| 2 |
Millennium Management
New York
|
-$13.6M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.31M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.96M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$4.59M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Acadian Asset Management
Boston,
Massachusetts
| – | -$76K | -15,932 | Closed |
|
|
AIM
177
Aigen Investment Management
New York
| – | -$67K | -13,984 | Closed |
|
178
Allianz Asset Management
Munich,
Germany
| – | -$65K | -13,637 | Closed |
|
|
CWS
179
Cypress Wealth Services
Palm Desert,
California
| – | -$42.9K | -10,000 | Closed |
|
|
PPCM
180
Pillar Pacific Capital Management
Pacifica,
California
| – | -$48K | -10,000 | Closed |
|
181
William Blair & Company
Chicago,
Illinois
| – | -$48K | -10,000 | Closed |
|
|
PHK
182
Point72 Hong Kong
Hong Kong
| – | -$34K | -7,184 | Closed |
|
|
FDCDDQ
183
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$29.5K | -6,200 | Closed |
|
|
PAG
184
Private Advisor Group
Morristown,
New Jersey
| – | -$11K | -2,400 | Closed |
|
|
GWM
185
Geneos Wealth Management
Englewood,
Colorado
| – | -$5K | -1,200 | Closed |
|
186
US Bancorp
Minneapolis,
Minnesota
| – | -$5K | -1,000 | Closed |
|
|
EI
187
Ellevest Inc
New York
| – | +$51 | +12 | +63% |
|
|
PCS
188
Personal CFO Solutions
Chester,
New Jersey
| – | +$36.4K | +8,500 | +10% |
|
BCRX Hedge Fund Activity: Q3 2020 in Review
154 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2020, worth a combined $427M — down 33% from $635M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of BCRX and 25 opened new positions — a net loss of 10 holders — while 43 trimmed existing stakes and 62 added.
The largest buyer was Sarissa Capital Management, adding an estimated $16.2M. The largest seller was Eversept Partners, cutting an estimated $15.9M.
- 154 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2020, down from 165 in Q2 2020.
- Funds reported $427M of BioCryst Pharmaceuticals stock for Q3 2020, down 33% quarter-over-quarter.
- 25 funds opened new BioCryst Pharmaceuticals positions in Q3 2020 and 35 closed out, a net change of -10 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2020 was Sarissa Capital Management, an estimated $16.2M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2020 was Eversept Partners, an estimated $15.9M sold.
Based on aggregated 13F filings for Q3 2020.